BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 7923123)

  • 1. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene.
    Yue W; Zhou D; Chen S; Brodie A
    Cancer Res; 1994 Oct; 54(19):5092-5. PubMed ID: 7923123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
    Yue W; Wang J; Savinov A; Brodie A
    Cancer Res; 1995 Jul; 55(14):3073-7. PubMed ID: 7606729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
    Brodie A; Jelovac D; Long BJ
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):455S-9S. PubMed ID: 12538500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
    Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A
    Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
    Osborne CK; Hobbs K; Clark GM
    Cancer Res; 1985 Feb; 45(2):584-90. PubMed ID: 3967234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation.
    Yue W; Wang JP; Hamilton CJ; Demers LM; Santen RJ
    Cancer Res; 1998 Mar; 58(5):927-32. PubMed ID: 9500452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse.
    Robinson SP; Jordan VC
    Cancer Res; 1989 Apr; 49(7):1758-62. PubMed ID: 2522347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
    Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
    Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.
    Foster PA; Chander SK; Newman SP; Woo LW; Sutcliffe OB; Bubert C; Zhou D; Chen S; Potter BV; Reed MJ; Purohit A
    Clin Cancer Res; 2008 Oct; 14(20):6469-77. PubMed ID: 18927286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice.
    McLeskey SW; Kurebayashi J; Honig SF; Zwiebel J; Lippman ME; Dickson RB; Kern FG
    Cancer Res; 1993 May; 53(9):2168-77. PubMed ID: 8481920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
    Belosay A; Brodie AM; Njar VC
    Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
    Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
    Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors: rationale for use following antiestrogen therapy.
    Yue W; Santen RJ
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):21-7. PubMed ID: 8824461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
    Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
    Sonne-Hansen K; Lykkesfeldt AE
    J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
    Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A
    Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
    Sabnis G; Brodie A
    Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
    Brodie AH; Jelovac D; Long B
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):283-8. PubMed ID: 14623522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.